Caliber Wealth Management LLC KS Decreases Position in Merck & Co., Inc. $MRK

Caliber Wealth Management LLC KS lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 73.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,269 shares of the company’s stock after selling 22,499 shares during the period. Caliber Wealth Management LLC KS’s holdings in Merck & Co., Inc. were worth $655,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Peoples Financial Services CORP. raised its holdings in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock valued at $1,803,000 after purchasing an additional 122 shares in the last quarter. McLean Asset Management Corp raised its holdings in shares of Merck & Co., Inc. by 3.7% in the 2nd quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock valued at $292,000 after purchasing an additional 125 shares in the last quarter. Cora Capital Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 2.4% in the 2nd quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock valued at $423,000 after purchasing an additional 125 shares in the last quarter. Saiph Capital LLC raised its holdings in shares of Merck & Co., Inc. by 3.7% in the 1st quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock valued at $320,000 after purchasing an additional 128 shares in the last quarter. Finally, Physician Wealth Advisors Inc. raised its holdings in shares of Merck & Co., Inc. by 2.9% in the 2nd quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company’s stock valued at $363,000 after purchasing an additional 128 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of analyst reports. Morgan Stanley reduced their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Wells Fargo & Company dropped their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 price objective on the stock. Finally, Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Hold” and a consensus price target of $104.33.

Merck & Co., Inc. Stock Down 0.0%

Shares of NYSE:MRK opened at $87.60 on Thursday. The company has a market cap of $218.81 billion, a price-to-earnings ratio of 13.50, a PEG ratio of 0.96 and a beta of 0.37. The firm’s 50-day simple moving average is $84.28 and its 200-day simple moving average is $81.43. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $107.36.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.10. The business had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.